4Q EARNINGS: Celgene growth on track for 2015 and beyond
This article was originally published in Scrip
Executive Summary
There were no surprises in Celgene's fourth quarter and year-end 2014 earnings report, since the company gave investors guidance through 2020 earlier in January, but Celgene is on track to diversify beyond its market-leading multiple myeloma drug Revlimid (lenalidomide) through ongoing research and development as well as continued dealmaking.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.